Halozyme appoints new president, CEO
The company has promoted Michael Shepard as the chief scientific officer after having joined the company as vice president of discovery research. Halozyme president and CEO Gregory Frost
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.